- Home
- SEMR vs DNTH Comparison
SEMR vs DNTH Comparison
Compare SEMR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEMR | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEMR | DNTH |
|---|---|---|
| Price | $11.91 | $36.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $13.80 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 1.1M | 646.9K |
| Earning Date | 02-25-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $428,627,000.00 | $3,078,000.00 |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $14.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.87 | N/A |
| 52 Week Low | $6.56 | $13.37 |
| 52 Week High | $18.74 | $45.46 |
Technical Indicators
Market Signals| Indicator | SEMR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 80.51 | 30.88 |
| Support Level | $11.87 | $40.79 |
| Resistance Level | $11.90 | $43.40 |
| Average True Range (ATR) | 0.03 | 1.90 |
| MACD | -0.13 | -0.83 |
| Stochastic Oscillator | 81.25 | 7.60 |
Price Performance
Historical ComparisonAbout SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.